Download PDF
Hamostaseologie 1989; 09(05): 3-8
DOI: 10.1055/s-0038-1655274
Editorial
Schattauer GmbH

Niedermolekulare Heparine

H. K. Breddin
,
R. Schmutzler
Further Information

Publication History

Publication Date:
25 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • LITERATUR

  • 1 Andriuoli G, Mastacchi R, Barbanti M, Sarret M. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 1985; 15: 324-30.
    PubMedSearch in Google Scholar
  • 2 Barrowcliffe T W, Johnson E A, Eggleton C A, Kemball-Cook G, Thomas D R. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haemat 1979; 41: 573-83.
    CrossrefPubMedSearch in Google Scholar
  • 3 Barrowcliffe T W, Curtis A D, Tomkinson T P, Hubbard A R, Johnson E A, Thomas D R. Standardisation of low molecular weight heparins: a collaborative study. Thromb Haemostas 1985; 54: 675-79.
    PubMedSearch in Google Scholar
  • 3a Beguin S, Choay J, Hemker C. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemostas 1989; 61: 397-401.
    PubMedSearch in Google Scholar
  • 4 Bender N, Seidl C, Weichert W, Breddin H K. Evaluation of the biological effects of lowmolecular-weight heparins. Haemostasis 1988; 18 (Suppl. 03) 23-32.
    PubMedSearch in Google Scholar
  • 5 Carter C J, Kelton J G, Hirsh J, Cerskus A, Santos A V, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-45.
    PubMedSearch in Google Scholar
  • 6 Choay J. Chemically synthetized heparin-derived oligosaccharides. In: Ofosu F A, Danishefsky I, Hirsh J. (eds). Heparin and Related Polysaccharides. New York: New York Academy of Sciences; 1989: 61-74.
    Search in Google Scholar
  • 7 Esquivel C O, Bergqvist D, Björck C-G, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res 1982; 28: 389-99.
    CrossrefPubMedSearch in Google Scholar
  • 8 Fareed J, Kumar A, Walenga J M, Emanuelle R M, Williamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hematol 1984; 26: 267-75.
    PubMedSearch in Google Scholar
  • 9 Fareed J, Walenga J M, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular weight heparins. Haemostasis 1988; 18 (Suppl. 03) 3-15.
    PubMedSearch in Google Scholar
  • 10 Harenberg J. Relation of antifactor Xa activity of heparins and antithrombotic efficacy. Haemostasis 1988; 18 (Suppl. 03) 16-9.
    PubMedSearch in Google Scholar
  • 11 Hemker H C, Beguin S, Pieters J, Lindhout T. The ex vivo correlate of the antithrombotic action of heparin. In: Ofosu F A, Danishefsky I, Hirsh J. (eds). Heparin and Related Polysaccharides. New York: New York Academy of Sciences; 1989: 146-57.
    Search in Google Scholar
  • 12 Hirsh J, Ofosu F A, Levine M. The development of low molecular weight heparins for clinical use. In: Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds). Thrombosis and Haemostasis. Leuven: Leuven Univ Press; 1987: 325-48.
    Search in Google Scholar
  • 13 Kakkar V V, Nicolaides A N, Field E S, Flute P T, Wessler S, Yin E T. Low doses of heparin in prevention of deep-vein thrombosis. Lancet 1971; II: 669-71.
    PubMedSearch in Google Scholar
  • 14 Kakkar V V, Spindler J, Flute P T, Corrigan T, Fossard D P, Crellin R Q, Wessler S, Yin E T. Efficacy of low doses of heparin in prevention of deep vein thrombosis after major surgery. Lancet 1972; II: 101-6.
    PubMedSearch in Google Scholar
  • 15 Kakkar V V, Corrigan T P, Fossard D P, Sutherland I, Shelton M G, Thirlwall J. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; II: 1-19.
    PubMedSearch in Google Scholar
  • 16 Maggi A, Barrowcliffe T W, Gray E, Donate M B, Merton R E, Pangrazzi I. Relationship between haemorrhagic and lipase-releasing properties of heparin and LMW heparins. Thromb Haemostas 1987; 58: 128.
    PubMedSearch in Google Scholar
  • 17 Ofosu F A, Smith L M, Anvari N, Blajchman M A. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition. Thromb Haemostas 1988; 60: 193-8.
    PubMedSearch in Google Scholar
  • 18 Ofosu F A, Buchanan M R, Anvari N, Smith L M, Blajchman M A. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate. In: Ofosu F A, Danishefsky I, Hirsh J. (eds). Heparin and Related Polysaccharides. New York: New York Academy of Sciences; 1989: 123-31.
    Search in Google Scholar
  • 18a Raake W, Klauser R, Walenga J, Fareed J, Schumacher H. Studies on the antithrombotic actions of sulfated lactobionic acid derivatives. Thromb Haemostas 1989; 61: 169.
    PubMedSearch in Google Scholar
  • 19 Sharnoff J G. Results in the prophylaxis of postoperative thromboembolism. Surg Gynecol . Obstet 1966; 123: 303-7.
    PubMedSearch in Google Scholar
  • 20 Weichert W, Breddin H K. Effect of low molecular weight heparins on laser-induced thrombus formation in rat mesenteric vessels. Haemostasis 1988; 18 (Suppl. 03) 55-63.
    PubMedSearch in Google Scholar